These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

753 related items for PubMed ID: 16949243

  • 1. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR, Jones RN.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
    Rhomberg PR, Jones RN, Sader HS, Fritsche TR, MYSTIC Programme Study Group.
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
    [Abstract] [Full Text] [Related]

  • 4. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR, Deshpande LM, Kirby JT, Jones RN.
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [Abstract] [Full Text] [Related]

  • 5. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
    Rhomberg PR, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
    [Abstract] [Full Text] [Related]

  • 6. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [Abstract] [Full Text] [Related]

  • 7. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V, Ulusoy S, Zarakolu P, Mete B, Turkish MYSTIC Study Group.
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [Abstract] [Full Text] [Related]

  • 8. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    J Chemother; 2005 Oct; 17(5):459-69. PubMed ID: 16323433
    [Abstract] [Full Text] [Related]

  • 9. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [Abstract] [Full Text] [Related]

  • 10. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 11. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN, Kirby JT, Rhomberg PR.
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [Abstract] [Full Text] [Related]

  • 12. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
    Turner PJ.
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):281-9. PubMed ID: 15808320
    [Abstract] [Full Text] [Related]

  • 13. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Apr; 54(4):249-57. PubMed ID: 16466890
    [Abstract] [Full Text] [Related]

  • 14. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [Abstract] [Full Text] [Related]

  • 15. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
    Pascual A, Perea E, Alvarez M, Casal M, Garcia de Lomas J, Garcia Rodríguez JA, Martin R, Soria G, Zapardiel J, Spanish MYSTIC group.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
    [Abstract] [Full Text] [Related]

  • 16. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S, Garcia-Rodriguez JA.
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [Abstract] [Full Text] [Related]

  • 18. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
    Streit JM, Jones RN, Sader HS, Fritsche TR.
    Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
    [Abstract] [Full Text] [Related]

  • 19. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
    Pfaller MA, Jones RN.
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():25-37. PubMed ID: 11065146
    [Abstract] [Full Text] [Related]

  • 20. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW, Xu YC, Chen MJ, Hu YJ, Ni YX, Sun JY, Yu YS, Kong HS, He L, Wu WY, Ye HF, Yang YM, Zhu LN, Guo SH, Ji P, Zhu ZH, Ren JK, Zhang LX, Sun ZY, Zhu XH, Tong MQ, Zhao WS, Mei YN, Liu Y, Zhang ZJ, Duan Q, Li D, Liu PP, Wang J, Han LX, Wang H, Xie XL.
    Zhonghua Yi Xue Za Zhi; 2007 Oct 23; 87(39):2753-8. PubMed ID: 18167265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.